A Boston-based company working to improve the way drugs are brought to the market has secured $110 million in Series B funding from Koch Disruptive Technologies.
Valo Health LLC said in a press release that the investment from the division of Wichita-based Koch, Inc. Inc. closed its Series B at $300 million pushed its total funding past $450 million.
Founded in 2019, Valo aims to use artificial intelligence and machine learning to enhance drug discovery and development.
”We see Valo’s strategy and approach to transforming drug discovery and development as highly disruptive to the industry,” Chase Koch, president of Koch Disruptive Technologies, said in a press release. “Their machine learning and data-centric technology solutions will bring significant value to patients and healthcare practitioners looking for more efficient and enhanced treatment options. The medtech and health-care markets are currently undergoing dramatic change and accelerated transformation, and our investment in Valo is a testament not only to our belief in their mission but to the importance of this industry in general.”
